Mode
Text Size
Log in / Sign up
N/A N=273 Randomized Single-blind Treatment

New Dermal Filler for Lip Augmentation

Lip Augmentation

Enrolled (actual)
273
Serious AEs
0.7%
Results posted
Jun 2020
Primary outcome: Primary: Assess Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS) — 1.8; 1.7; 1.8; 1.8 Change in MLFS score from baseline

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
New Dermal Filler (Device); Device: FDA Approved Dermal Filler (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Galderma R&D
Primary completion
Jun 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Assess Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS)
1.8; 1.7; 1.8; 1.8
SECONDARY
Assess Effectiveness of the New Dermal Filler Treatment in the Upper & Lower Lips Using the Medicis Lip Fullness Scale
142; 129; 115; 110; 101
SECONDARY
Assess Effectiveness of the New Dermal Filler Treatment in the Upper & Lower Lips Using the Medicis Lip Fullness Scale
142; 129; 115; 110; 101
SECONDARY
Assess Aesthetic Improvement in the Perioral Rhytids & Oral Commissures After New Dermal Filler Treatment Using the Wrinkle Assessment Scale (Change From Baseline, Blinded Evaluator)
-2.2; -1.8; -1.7; -1.6; -1.5; -1.6
SECONDARY
Assess Aesthetic Improvement in the Perioral Rhytids & Oral Commissures After New Dermal Filler Treatment Using the Wrinkle Assessment Scale (Response Rates, Blinded Evaluator)
50; 47; 47; 47; 47; 44
SECONDARY
Assess Overall Aesthetic Improvement After New Dermal Filler Treatment Using the Global Aesthetic Improvement Scale Determined by Response Rates, Subject Assessment
170; 161; 148; 140; 131; 132
SECONDARY
Assess Overall Aesthetic Improvement After New Dermal Filler Treatment Using the Global Aesthetic Improvement Scale, Treating Investigator
175; 169; 145; 137; 121; 114
SECONDARY
Assessment of Improvement in Lip Fullness After New Dermal Filler Treatment, by Independent Photographic Reviewer
168; 164; 149; 144; 149; 138
SECONDARY
Assess Subject Satisfaction With New Dermal Filler Treatment Using the FACE-Q
28.1; 83.3; 76.2; 74.9; 72.0; 69.0

Summary

To demonstrate non-inferiority of Kysse versus a control in lip fullness augmentation

Eligibility Criteria

Inclusion Criteria

  • Subjects willing to comply with the requirements of the study and providing a signed written informed consent.
  • Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
  • Seeking augmentation therapy for the lips

Exclusion Criteria

  • Allergy of hypersensitivity to any injectable hyaluronic acid gel or to gram positive bacterial proteins.
  • Allergy or hypersensitivity to lidocaine or other amide-type anesthetics, or topical anesthetics or nerve blocking agents.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03320824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search